|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
0.20/0.32
|
Enterprise Value
2.75B
|
Balance Sheet |
Book Value Per Share
4.44
|
Cash Flow |
Cash Flow Yield
0.00
|
Income Statement |
Total Revenue
165.03M
|
Operating Revenue Per Share
4.43
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolioof several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures. |